The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. Each group is held to an annual re-election or rotation process, with nominations and approval by the ARM membership and current Board.
WASHINGTON, D.C., GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --
The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. Each group is held to an annual re-election or rotation process, with nominations and approval by the ARM membership and current Board.
“I am pleased to welcome new and returning ARM members to our organization’s 2019 slates of Officers, Executive Committee, and Board of Directors,” said Janet Lambert, CEO of ARM. “The ability to engage and collaborate with representatives from across ARM’s diverse multi-stakeholder membership is a valuable asset as we work to bring safe and effective regenerative medicine products to patients worldwide.”
ARM 2019 Officers:
Matthew Patterson – CEO, Audentes Therapeutics (Chairman)
Emile Nuwaysir, Ph.D. – President and CEO, BlueRock Therapeutics (Vice Chairman)
Amy Butler, Ph.D. – VP and GM Cell Biology, Thermo Fisher Scientific (Secretary)
Jeffrey Walsh – Chief Financial and Strategy Officer, bluebird bio (Treasurer)
ARM 2019 Executive Committee:
*new to the Executive Committee for 2019
* Amy Butler, Ph.D. – VP and GM Cell Biology, Thermo Fisher Scientific (Secretary)
Michael Hunt – Chief Financial Officer, ReNeuron
Michael May, Ph.D. – CEO, CCRM
* Emile Nuwaysir, Ph.D. – President and CEO, BlueRock Therapeutics (Vice Chairman)
Matthew Patterson – Co-Founder and CEO, Audentes Therapeutics (Chairman)
Martha Rook, Ph.D. – Head of Gene Editing and Novel Modalities, MilliporeSigma (EMD Millipore)
* Bob Smith – SVP, Global Gene Therapy Business, Pfizer
Philip Vanek, Ph.D. – GM, Cell and Gene Therapy Strategy, GE Healthcare Life Sciences
* Jeffrey Walsh – Chief Financial and Strategy Officer, bluebird bio (Treasurer)
ARM 2019 Board of Directors:
*new to the Board for 2019
Zami Aberman – Chairman and Co-CEO, Pluristem Therapeutics
Usman (‘Oz’) Azam, M.D. – President and CEO, Tmunity Therapeutics
Ronald Bartek – Co-Founder and President, Friedreich’s Ataxia Research Alliance
* Joanne Beck, Ph.D. – EVP, Global Pharmaceutical Development and Operations, Celgene Corporation
* James Burns, Ph.D. – President and CEO, Casebia Therapeutics
Amy Butler, Ph.D. – VP and GM Cell Biology, Thermo Fisher Scientific (Secretary)
Deborah Dean – EVP, MiMedx
Flagg Flanagan – Chairman and CEO, DiscGenics
* Miguel Forte, M.D., Ph.D. – CEO, Zelluna Immunotherapy
* Adam Gridley – President and CEO, Histogenics
* Kristen Harrington-Smith – VP and Head, CAR-T US, Novartis Oncology
Michael Hunt – Chief Financial Officer, ReNeuron
Paul Laikind, Ph.D. – President and CEO, ViaCyte
Bruce Levine, Ph.D. – Barbara and Edward Netter Professor in Cancer Gene Therapy, and Founding Director, Clinical Cell and Vaccine Production Facility, Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania
Michael May, Ph.D. – CEO, CCRM
* Claudia Mitchell, Ph.D. – COO, Universal Cells, An Astellas company
Emile Nuwaysir, Ph.D. – President and CEO, BlueRock Therapeutics (Vice Chairman)
Matthew Patterson – Co-Founder and CEO, Audentes Therapeutics (Chairman)
* Derrell Porter, M.D. – SVP, Global Commercial Head, Atara Biotherapeutics
Isabelle Riviere, Ph.D. – Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
Martha Rook, Ph.D. – Head of Gene Editing and Novel Modalities, MilliporeSigma (EMD Millipore)
Sanjaya Singh, Ph.D. – VP and Global Head, Janssen BioTherapeutics, Janssen R&D, Janssen Pharmaceutical Companies of Johnson & Johnson,
Donna Skerrett, M.D. – Chief Medical Officer, Mesoblast Limited
Bob Smith – SVP, Global Gene Therapy Business, Pfizer
* Devyn Smith, Ph.D. – Chief Strategy Officer and Head of Operations, Sigilon Therapeutics
Joseph Tarnowski, Ph.D. – SVP, Cell and Gene Therapy Platform, GlaxoSmithKline
Keith Thompson – CEO, Cell and Gene Therapy Catapult
* Arthur Tzianabos, Ph.D. – President and CEO, Homology Medicines
Gil Van Bokkelen, Ph.D. – Chairman and CEO, Athersys
Philip Vanek, Ph.D. – GM, Cell and Gene Therapy Strategy, GE Healthcare Life Sciences
Jeffrey Walsh – Chief Financial and Strategy Officer, bluebird bio (Treasurer)
Sue Washer – President and CEO, AGTC
Jason Wertheim, M.D., Ph.D. – Edward G. Elcock Professor of Surgical Research and Associate Professor, Division of Transplantation Northwestern University
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 300 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
Lyndsey Scull 202 213 7086 lscull@alliancerm.org
